lead the future!

Yesterday, the Endpoints News website published a list of 20 global leaders in the biomedicine field under the age of 40 in 2021.
At the beginning of the list, they pointed out that they are leading the most cutting-edge research in the industry and may subvert the development direction of the industry.
They are a new generation of industry leaders.

Yesterday, the Endpoints News website published a list of 20 global leaders in the biomedicine field under the age of 40 in 2021.
At the beginning of the list, they pointed out that they are leading the most cutting-edge research in the industry and may subvert the development direction of the industry.
They are a new generation of industry leaders.

Ranjan Batra Company: LocanaBio Age: 38 Endpoints Comment: Use RNA therapy for the treatment of Huntington's Disease

Ranjan Batra Company: LocanaBio Age: 38 Endpoints Comment: Use RNA therapy for the treatment of Huntington's Disease

San Diego-based LocanaBio is committed to the development of innovative gene therapies to cure a variety of diseases, including neuromuscular diseases, neurodegenerative diseases and retinal diseases, by modifying disease-related dysfunctional RNA.
As the company's vice president of research and development, Dr.
Ranjan Batra is advancing the application of RNA therapy to the treatment of Huntington's disease.

San Diego-based LocanaBio is committed to the development of innovative gene therapies to cure a variety of diseases, including neuromuscular diseases, neurodegenerative diseases and retinal diseases, by modifying disease-related dysfunctional RNA.
As the company's vice president of research and development, Dr.
Ranjan Batra is advancing the application of RNA therapy to the treatment of Huntington's disease.
 

LocanaBio's technology platform combines gene therapy and RNA modification technologies to treat a variety of diseases.
By loading the RNA modification system on an adeno-associated virus (AAV) vector, the RNA modification system is delivered to the target tissue.
RNA binding protein and its effector domains can regulate dysfunctional RNA and cure diseases through a variety of mechanisms, including degrading dysfunctional RNA molecules, degrading dysfunctional RNA molecules and replacing them with normal genes, and enhancing RNA translation.
Produce more specific proteins, modified splicing and RNA editing.

Florian Brand Company: ATAI Life Sciences Age: 34 Endpoints Comment: Develop innovative therapies for various mental health indications

As one of the founders of ATAI Life Sciences, Mr.

Florian Brand is advancing the company's development of psychedelic and non-psychedelic compounds for various mental health indications.
The company was established in 2018 and is headquartered in Berlin, Germany.

As one of the founders of ATAI Life Sciences, Mr.

Founded in 2016, Forty Seven is a biomedical company dedicated to targeting cancer immune escape pathways.
The company's technology is based on the scientific research of Stanford University, and its founder is Professor Irv Weissman of Stanford University.
The company's main research and development project is an anti-CD47 monoclonal antibody called 5F9 (magrolimab).
Dr.
Mark Chao is a student of Professor Irv Weissman.
Many of the technological breakthroughs of magrolimab are related to Dr.
Mark Chao.
In March 2020, Gilead Sciences announced that it had reached a final agreement with Forty Seven.
Gilead will acquire Forty Seven for a total transaction value of approximately US$4.
9 billion.
Now, as the vice president of clinical research at Gilead Oncology, Dr.
Mark Chao is advancing the development of innovative therapies for AML.

Founded in 2016, Forty Seven is a biomedical company dedicated to targeting cancer immune escape pathways.
The company's technology is based on the scientific research of Stanford University, and its founder is Professor Irv Weissman of Stanford University.
The company's main research and development project is an anti-CD47 monoclonal antibody called 5F9 (magrolimab).
Dr.
Mark Chao is a student of Professor Irv Weissman.
Many of the technological breakthroughs of magrolimab are related to Dr.
Mark Chao.
In March 2020, Gilead Sciences announced that it had reached a final agreement with Forty Seven.
Gilead will acquire Forty Seven for a total transaction value of approximately US$4.
9 billion.
Now, as the vice president of clinical research at Gilead Oncology, Dr.
Mark Chao is advancing the development of innovative therapies for AML.

Emily Drabant Conley Company: Federation Bio 
Age: 35 Endpoints Comment: From genetics to microbiome, Emily Drabant Conley impresses us

Dr.

Emily Drabant Conley worked for 23andMe, a pioneering consumer genetic testing company for more than ten years, and helped the company build one of the largest genetic/phenotype databases in the world.
Dr.

Dr.

Seattle-based Athira Pharma focuses on the research and development of drugs for neurodegenerative diseases, including the main product under development, NDX-1017 for the treatment of Alzheimer's disease (AD).
In the past ten years, the research and development of AD drugs has been based on the strategy of reducing the deposition of beta amyloid.
In patients with Alzheimer's disease, beta-amyloid oligomers bind to receptors on the synapse, interfere with the function of the synapse, and cause abnormal synapses.
But this strategy has repeatedly failed in the past decade.
Athira company adopted a different strategy.
They tried to permanently change the course of the disease by activating key brain neurotrophic factors, restoring lost neural connections, or creating new neural connections.
NDX-1017 can target hepatocyte growth factor (HGF) and its receptor MET, promote the proliferation and survival of neurons, solve the underlying mechanism of neurodegenerative disease process, thereby improving the connection between brain nerve cells.
In the Phase 1b clinical trial of Athira, NDX-1017 also showed positive efficacy characteristics.
Dr.
Leen Kawas is leading the development of related therapies.

Seattle-based Athira Pharma focuses on the research and development of drugs for neurodegenerative diseases, including the main product under development, NDX-1017 for the treatment of Alzheimer's disease (AD).
In the past ten years, the research and development of AD drugs has been based on the strategy of reducing the deposition of beta amyloid.
In patients with Alzheimer's disease, beta-amyloid oligomers bind to receptors on the synapse, interfere with the function of the synapse, and cause abnormal synapses.
But this strategy has repeatedly failed in the past decade.
Athira company adopted a different strategy.
They tried to permanently change the course of the disease by activating key brain neurotrophic factors, restoring lost neural connections, or creating new neural connections.
NDX-1017 can target hepatocyte growth factor (HGF) and its receptor MET, promote the proliferation and survival of neurons, solve the underlying mechanism of neurodegenerative disease process, thereby improving the connection between brain nerve cells.
In the Phase 1b clinical trial of Athira, NDX-1017 also showed positive efficacy characteristics.
Dr.
Leen Kawas is leading the development of related therapies.

Juliette Hordeaux University of Pennsylvania Age: 37 Endpoints Comment: Professor Jim Wilson's right-hand man

Dr.

Juliette Hordeaux is the senior director of the Translational Science Center of the University of Pennsylvania, dedicated to the research of new methods to reduce the toxicity of gene therapy.
AAV vector-based gene therapy has shown promising potential in the treatment of neurological diseases.

Dr.
Nicole Gaudelli is the head of gene editing technology at Beam.
The founders of Beam are three of the world’s top CRISPR experts-Dr.
David Liu from Harvard University, Dr.
Keith Joung from Massachusetts General Hospital, and Dr.
Feng Zhang from the Broad Institute.
The company aims to use CRISPR-based Base editing technology precisely modifies a single base in the genome to treat genetic diseases caused by point mutations in a single gene.
Dr.
Nicole Gaudelli has developed single-base editing technology, which can convert AT base pairs in DNA sequences into GC base pairs.
Single gene mutations are associated with many diseases, including sickle cell anemia, cystic fibrosis, Parkinson's disease, Alzheimer's disease, and many types of cancer.
The single-base editing technology developed by Dr.
Gaudelli is expected to help treat 50% of genetic diseases caused by single-gene mutations.

Marc Lajoie and Scott Boyken Company: Outpace Bio Age: 35 years old Endpoints comment: Marc Lajoie and Scott Boyken are reshaping the possibility of protein

Dr.
Marc Lajoie and Dr.
Scott Boyken co-founded Outpace Bio, serving as CEO and Chief Scientific Officer, respectively.
Cell therapy represented by CAR-T cell therapy has achieved remarkable results in the treatment of blood cancers.
However, as a kind of "living medicine", the characteristics of cell therapy are not completely controlled by scientists.
For example, after CAR-T therapy is injected into the patient, their proliferation, activation, and failure are not completely controllable, which may affect the safety or efficacy of the therapy.
Outpace's technology platform aims to design proteins and regulatory circuits with brand-new functions not found in nature through synthetic biology methods.
And use these new proteins and regulatory circuits to finely regulate the differentiation state and signal pathways of cells, so that they can produce the right effects at the right time, and ultimately improve the efficacy and safety of cell and gene therapy.

Joshua Liang Company: Clover Biology Age: 29 years old Endpoints comment: Promote the new crown vaccine of CEPI (Epidemic Prevention Innovation Alliance) and Clover Biology

Mr.
Liang Guo is the CEO of Clover Biology and the co-inventor of the "S-trimer" vaccine.
Shamrock Bio uses its innovative and unique Trimer-Tag© (protein trimerization) technology platform to continue to develop and expand the R&D pipeline, including recombinant protein vaccines and tumor biological therapies.
Clover Biology plans to launch SCB-2019 ("S-trimer" recombinant protein subunit new crown vaccine candidate) worldwide phase 2/3 clinical effectiveness trials and vaccine production plans in the first half of 2021.
In addition, Clover Biology has also initiated the development of other vaccine projects, including multivalent new coronaviruses (covering a variety of new coronavirus variants), rabies and influenza vaccines.
Clover Biology plans to advance a variety of new R&D pipeline varieties to the clinical trial stage in 2021.

Sean McClain Company: AbSci Age: 31 Endpoints Comment: Sean McClain aims to simplify protein production

Sean McClain is the founder and CEO of AbSci.
AbSci is a synthetic biology company dedicated to redefining the production process of protein drugs.
The company has a proprietary SoluPro E.
coli expression system and Protein Printing platform.
Based on the deep learning Denovium Engine platform, the company is able to create new biotherapeutics and cell lines to produce them.
In this process, the company will select a cell line that can produce the best target potency and affinity, and at the same time can highly express the candidate drug.
According to the company's official website, AbSci focuses on the development of a new generation of biological products based on complex protein scaffolds.
The time for drug discovery and development will be shortened from several years to several weeks, and the resulting cell lines can be used for GMP production.

Ben Oakes Company: Scribe Therapeutics Age: 32 Endpoints Comment: Ben Oakes is leading the gene editing startup Scribe Therapeutics

Ben OakesScribe Therapeutics。ScribeCasX：CasX“”（uncultivated microbes），Cas9Cas12a，CasX（1000），，。Scribe，。，CRISPR ，、。
Imogen Pryce ：Relay Therapeutics：38 Endpoints：Imogen PryceRelay Therapeutics

Imogen PryceRelay Therapeutics。Relay“Dynamo”。，，。，，。RelayDynamo。“”，。，，，。，Relay。
Glenn Rockman ：Adjuvant Capital：39 Endpoints：Glenn Rockman

Glenn Rockman（JP Morgan），，·，。Adjuvant Capital，20212，3。Excision BiosciencesYisheng Biopharma，ExcisionCRISPRHIV。
Jake Rubens ：Flagship Pioneering：33 Endpoints：Jake Rubens，

Jake RubensFlagship Pioneering。Tessera TherapeuticsRubens，TesseraFlagship Pioneering，。，。，。
Carol SuhChristina Trojel-Hansen ：ARCH Venture：3238 Endpoints：

Carol SuhChristina Trojel-HansenARCH Venture（Entrepreneur-in-Residence）。ARCH，1ARCH Venture XI，18.
5。ARCH，，ARCH、、。ARCH，。，ARCH，GRAIL、bluebird bio、Beam Therapeutics、Alnylam Pharmaceuticals、Denali Therapeutics。

Laura Walker ：Adagio：36 Endpoints：Laura Walker-Adagio

Laura WalkerAdagio。，““，，，90%。Adagio、SARS-CoV-1““。，，。